Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Non Operating Income (2017 - 2023)

Denali Therapeutics has reported Non Operating Income over the past 7 years, most recently at $13.1 million for Q4 2023.

  • Quarterly Non Operating Income rose 97.13% to $13.1 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $51.5 million through Dec 2023, up 248.62% year-over-year, with the annual reading at $51.5 million for FY2023, 248.62% up from the prior year.
  • Non Operating Income was $13.1 million for Q4 2023 at Denali Therapeutics, down from $14.4 million in the prior quarter.
  • Over five years, Non Operating Income peaked at $14.4 million in Q3 2023 and troughed at $1.0 million in Q3 2021.
  • The 5-year median for Non Operating Income is $3.1 million (2020), against an average of $4.8 million.
  • Year-over-year, Non Operating Income crashed 61.58% in 2021 and then skyrocketed 763.38% in 2023.
  • A 5-year view of Non Operating Income shows it stood at $3.8 million in 2019, then crashed by 56.9% to $1.6 million in 2020, then fell by 21.17% to $1.3 million in 2021, then soared by 418.29% to $6.7 million in 2022, then soared by 97.13% to $13.1 million in 2023.
  • Per Business Quant, the three most recent readings for DNLI's Non Operating Income are $13.1 million (Q4 2023), $14.4 million (Q3 2023), and $12.9 million (Q2 2023).